90%Confidence
0Views
FDASource
2026-04-09Date
Summary
Another Class II recall for Teva's Octreotide Acetate 10mg variant reinforces systemic sterility issues at the same Greek contract manufacturer, indicating a broader problem across multiple dosage strengths. This repeated failure may trigger FDA enforcement actions and necessitate finding alternative suppliers, increasing operational costs.
Actionable: Investigate Teva's contingency plans for manufacturing Octreotide Acetate to anticipate supply chain adjustments.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now